Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF)

Next Previous
Search
Trial Profile

A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexotegrast (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms INTEGRIS-IPF
  • Sponsors Pliant Therapeutics

    • Most Recent Events

    • 10 Sep 2024 According to a Pliant Therapeutics media release, integrated safety summary of bexotegrast from the INTEGRIS-IPF and INTEGRIS-PSC were presented at the European Respiratory Society (ERS) International Congress 2024 taking place in Vienna, Austria September 7-11, 2024.
    • 26 Aug 2024 According to a Pliant Therapeutics media release, data from this study will be presented at the European Respiratory Society (ERS) International Congress 2024. The Congress will take place in Vienna, Austria from September 7 - 11, 2024.
    • 22 May 2024 Results presented at the 120th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top